{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:22:18Z","timestamp":1770330138347,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":3510,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1111\/jth.12172","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T11:25:46Z","timestamp":1360841146000},"page":"855-861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial"],"prefix":"10.1016","volume":"11","author":[{"given":"M.","family":"Raps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rosendaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ballieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Helmerhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12172_bb0010","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJM200105173442007","article-title":"Oral contraceptives and the risk of venous thrombosis","volume":"344","author":"Vandenbroucke","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12172_bb0015","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1046\/j.1538-7836.2003.00264.x","article-title":"Estrogens, progestogens and thrombosis","volume":"1","author":"Rosendaal","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12172_bb0020","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case\u2013control study","volume":"339","author":"van","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/jth.12172_bb0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/jth.12172_bb0030","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/jth.12172_bb0035","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"10.1111\/jth.12172_bb0040","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/jth.12172_bb0045","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1538-7836.2010.04148.x","article-title":"Hormone therapies and venous thromboembolism: where are we now?","volume":"9","author":"van","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12172_bb0050","doi-asserted-by":"crossref","first-page":"d2151","DOI":"10.1136\/bmj.d2151","article-title":"Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case\u2013control study using United States claims data","volume":"342","author":"Jick","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/jth.12172_bb0055","doi-asserted-by":"crossref","first-page":"d2139","DOI":"10.1136\/bmj.d2139","article-title":"Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case\u2013control study based on UK General Practice Research Database","volume":"342","author":"Parkin","year":"2011","journal-title":"BMJ"},{"key":"10.1111\/jth.12172_bb0060","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/jth.12172_bb0065","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/j.1538-7836.2004.00983.x","article-title":"Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate","volume":"2","author":"van Vliet","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12172_bb0070","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography","volume":"98","author":"Tchaikovski","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12172_bb0075","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2003.04443.x","article-title":"Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women","volume":"122","author":"Tans","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.12172_bb0080","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/j.1538-7836.2012.04720.x","article-title":"Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives","volume":"10","author":"Raps","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12172_bb0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/jth.12054","article-title":"Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone binding globulin levels in premenopausal women","volume":"11","author":"Stegeman","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12172_bb0090","first-page":"482","article-title":"Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?","volume":"81","author":"Odlind","year":"2002","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1111\/jth.12172_bb0095","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2008.11.002","article-title":"Sex hormone-binding globulin: an adequate surrigate marker for venous thromboembolism in women using new hormonal contraceptives","volume":"79","author":"van Vliet","year":"2009","journal-title":"Contraception"},{"key":"10.1111\/jth.12172_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/humrep\/deh612","article-title":"Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens","volume":"20","author":"van Vliet","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1111\/jth.12172_bb0105","series-title":"Greenspan's Basic & Clinical Endocrinology","author":"Gardner","year":"2007"},{"key":"10.1111\/jth.12172_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0010-7824(90)90034-S","article-title":"Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone","volume":"41","author":"van der Vange","year":"1990","journal-title":"Contraception"},{"key":"10.1111\/jth.12172_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0010-7824(00)00196-7","article-title":"Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel","volume":"63","author":"Knopp","year":"2001","journal-title":"Contraception"},{"key":"10.1111\/jth.12172_bb0120","series-title":"Progestins and Antiprogestins in Clinical Practice","author":"Sitruk-Ware","year":"2000"},{"key":"10.1111\/jth.12172_bb0125","series-title":"Medical eligibility criteria for contraceptive use","year":"2009"},{"key":"10.1111\/jth.12172_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0010-7824(02)00436-5","article-title":"Effect of four different oral contraceptives on various sex hormones and serum-binding globulins","volume":"67","author":"Wiegratz","year":"2003","journal-title":"Contraception"},{"key":"10.1111\/jth.12172_bb0135","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0010-7824(95)00098-U","article-title":"Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins","volume":"51","author":"Wiegratz","year":"1995","journal-title":"Contraception"},{"key":"10.1111\/jth.12172_bb0140","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","article-title":"A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways","volume":"84","author":"Tans","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12172_bb0145","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/11591200-000000000-00000","article-title":"Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate\/dienogest versus ethinylestradiol\/levonorgestrel","volume":"11","author":"Klipping","year":"2011","journal-title":"Drugs R D."},{"key":"10.1111\/jth.12172_bb0150","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/11590220-000000000-00000","article-title":"Metabolic and haemostatic effects of estradiol valerate\/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study","volume":"31","author":"Junge","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1111\/jth.12172_bb0155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0091270006297919","article-title":"Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive","volume":"47","author":"Devineni","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jth.12172_bb0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.contraception.2008.04.004","article-title":"Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives","volume":"78","author":"Stanczyk","year":"2008","journal-title":"Contraception"},{"key":"10.1111\/jth.12172_bb0165","first-page":"1","article-title":"Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group","volume":"877","year":"1998","journal-title":"World Health Organ Tech Rep Ser"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12172","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362213610X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153878362213610X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12172\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:08:12Z","timestamp":1761534492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362213610X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S153878362213610X"],"URL":"https:\/\/doi.org\/10.1111\/jth.12172","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}